SK278444B6 - Substituted 5-arylpyrimidine, manufacturing process thereof and pharmaceutical composition containing its - Google Patents

Substituted 5-arylpyrimidine, manufacturing process thereof and pharmaceutical composition containing its Download PDF

Info

Publication number
SK278444B6
SK278444B6 SK1643-91A SK164391A SK278444B6 SK 278444 B6 SK278444 B6 SK 278444B6 SK 164391 A SK164391 A SK 164391A SK 278444 B6 SK278444 B6 SK 278444B6
Authority
SK
Slovakia
Prior art keywords
acid
pyrimidine
trichlorophenyl
amino
compound
Prior art date
Application number
SK1643-91A
Other languages
English (en)
Slovak (sk)
Inventor
Michael J Leach
Malcolm S Nobbs
Ramachandran Iyer
Clive L Yeates
Philip A Skone
Original Assignee
Leach Michael J.
Nobbs Malcolm S.
Ramachandran Iyer
Yeates Clive L.
Skone Philip A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leach Michael J., Nobbs Malcolm S., Ramachandran Iyer, Yeates Clive L., Skone Philip A. filed Critical Leach Michael J.
Publication of SK278444B6 publication Critical patent/SK278444B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Paper (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK1643-91A 1990-06-01 1991-05-31 Substituted 5-arylpyrimidine, manufacturing process thereof and pharmaceutical composition containing its SK278444B6 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909012316A GB9012316D0 (en) 1990-06-01 1990-06-01 Pharmacologically active cns compounds

Publications (1)

Publication Number Publication Date
SK278444B6 true SK278444B6 (en) 1997-05-07

Family

ID=10676964

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1643-91A SK278444B6 (en) 1990-06-01 1991-05-31 Substituted 5-arylpyrimidine, manufacturing process thereof and pharmaceutical composition containing its

Country Status (25)

Country Link
EP (2) EP0459819B1 (da)
JP (1) JPH06340634A (da)
KR (1) KR920000733A (da)
AT (1) ATE141263T1 (da)
AU (2) AU652753B2 (da)
CA (1) CA2043640A1 (da)
CZ (1) CZ281070B6 (da)
DE (1) DE69121317T2 (da)
DK (1) DK0459819T3 (da)
ES (1) ES2093078T3 (da)
FI (1) FI912623A (da)
GB (1) GB9012316D0 (da)
GR (1) GR3021237T3 (da)
HU (2) HUT58707A (da)
IE (1) IE911861A1 (da)
IL (2) IL98330A (da)
MY (2) MY109958A (da)
NO (1) NO180375C (da)
NZ (3) NZ272001A (da)
PL (2) PL166656B1 (da)
PT (1) PT97827B (da)
RU (1) RU2091374C1 (da)
SK (1) SK278444B6 (da)
TW (1) TW224460B (da)
ZA (1) ZA914165B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
MY110880A (en) * 1991-01-30 1999-06-30 The Wellcome Foundation Ltd Water-dispersible tablets
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
GB9226377D0 (en) * 1992-12-18 1993-02-10 Babbedge Rachel C Pharmaceutical compositions
JPH08504798A (ja) * 1992-12-18 1996-05-21 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9319341D0 (en) * 1993-09-17 1993-11-03 Wellcome Found Novel process
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
CA2383466C (en) 1999-09-16 2009-08-25 Tanabe Seiyaku Co., Ltd. Aromatic nitrogen-containing 6-membered cyclic compounds
US7220736B2 (en) 2000-04-28 2007-05-22 Tanabe Seiyaku Co., Ltd. Pyrimidine compounds
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
JP5154728B2 (ja) * 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ，インコーポレイテッド 神経栄養活性を有する置換５−アルキニルピリミジン
WO2002068419A1 (fr) 2001-02-26 2002-09-06 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
AU2003203148A1 (en) * 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
EP2386554A1 (en) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Compounds active at the histamine H3 receptor
WO2007135111A1 (en) 2006-05-23 2007-11-29 High Point Pharmaceuticals, Llc 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
EP2079732B9 (en) 2006-05-29 2012-03-21 High Point Pharmaceuticals, LLC 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
KR20140007954A (ko) 2011-06-10 2014-01-20 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
BR112018075663A2 (pt) 2016-06-14 2019-04-09 Novartis Ag compostos e composições para a inibição da atividade de shp2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE518622A (da) *
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds

Also Published As

Publication number Publication date
ATE141263T1 (de) 1996-08-15
CZ281070B6 (cs) 1996-06-12
ZA914165B (en) 1993-03-01
AU7809791A (en) 1991-12-05
MY136248A (en) 2008-08-29
JPH06340634A (ja) 1994-12-13
IE911861A1 (en) 1991-12-04
NZ248501A (en) 1997-03-24
NZ272001A (en) 1997-03-24
ES2093078T3 (es) 1996-12-16
AU680252B2 (en) 1997-07-24
IL98330A0 (en) 1992-06-21
EP0459819B1 (en) 1996-08-14
MY109958A (en) 1997-10-31
FI912623A0 (fi) 1991-05-31
KR920000733A (ko) 1992-01-29
AU652753B2 (en) 1994-09-08
EP0679645A1 (en) 1995-11-02
PT97827B (pt) 1998-10-30
GR3021237T3 (en) 1997-01-31
HU211649A9 (en) 1995-12-28
IL113599A (en) 1997-09-30
NO180375C (no) 1997-04-09
IL113599A0 (en) 1995-08-31
CA2043640A1 (en) 1991-12-02
NO912100D0 (no) 1991-05-31
NZ238360A (en) 1997-03-24
TW224460B (da) 1994-06-01
PL166656B1 (pl) 1995-06-30
DE69121317D1 (de) 1996-09-19
HU911826D0 (en) 1991-12-30
RU2091374C1 (ru) 1997-09-27
DE69121317T2 (de) 1997-01-02
DK0459819T3 (da) 1996-09-02
PL170373B1 (pl) 1996-12-31
HUT58707A (en) 1992-03-30
AU6745594A (en) 1994-09-15
EP0459819A2 (en) 1991-12-04
GB9012316D0 (en) 1990-07-18
EP0459819A3 (en) 1992-03-11
CS164391A3 (en) 1992-02-19
PT97827A (pt) 1992-03-31
NO912100L (no) 1991-12-02
FI912623A (fi) 1991-12-02
NO180375B (no) 1996-12-30
IL98330A (en) 1996-10-31

Similar Documents

Publication Publication Date Title
SK278444B6 (en) Substituted 5-arylpyrimidine, manufacturing process thereof and pharmaceutical composition containing its
US6440965B1 (en) Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US5684005A (en) Pharmacologically active CNS compounds
US5589477A (en) Pyrimidine derivatives and drugs
US5136080A (en) Nitrile compounds
JP2002541245A (ja) 神経栄養置換ピリミジン
EP2350026A1 (de) Sulfoximinsubstituierte anilinopyrimidinderative als cdk-inhibitoren, deren herstellung und verwendung als arzeinmittel
WO1996034856A1 (en) 2-ureido-benzamide derivatives
EP1751155B1 (de) Substituierte azachinazoline mit antiviraler wirkung
DE60020692T2 (de) Carbamoyltetrahydropyridin-derivate
SI9010607A (en) Pharmacologically active cns compounds